Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France’s Gemme Claims A Victory With Price-Cut Reversal

Moratorium On Price Cuts Accompanies Targeted Increases To Address Shortages

Executive Summary

French generics industry association Gemme has claimed a major victory in shifting the country’s policy on generic price cuts, after the government announced a moratorium on price reductions as well as targeted price increases for certain key locally-produced generics.

You may also be interested in...



French Proposals On Supply-Chain Security ‘Could Aggravate The Situation’

Proposed French legislation that would address shortages by strengthening obligations to hold security stocks – with the threat of sanctions for suppliers – would be counter-productive, local generics industry association Gemme has warned.

Medicines For Europe’s Sieger: ‘We Have To Create An Ecosystem Where We Can Compete’

Markus Sieger, vice-president of off-patent industry association Medicines for Europe and CEO of Polpharma, spoke to Generics Bulletin about critical issues affecting supply in Europe, including pricing, supply chains, and his enthusiasm for ESG.

Olon CEO Says European Systems Must Value Security Of Supply

With Olon investing significantly in its production capacity and technical capabilities, CEO Paolo Tubertini believes the API specialist is well-positioned to provide resilience within the European supply chain. However, the chief executive also told Generics Bulletin that this robustness needs to be valued by pricing mechanisms.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel